Table 4 Morbidity in children who received SP plus AQ or placebo during the malaria transmission period
| Â | Placebo (person months at risk, 2279) | SP/AQ (person months at risk, 2248) | Â | Â | ||
|---|---|---|---|---|---|---|
Outcome | Events | Incidence rate/100 person months | Events | Incidence rate/100 person months | Protective efficacy (95% CI) | P |
Total outpatient visits | 142 | 6.2 | 155 | 6.9 | -11% (-42%, 14%) | 0.42 |
Anaemia (Hb < 11 g/dL) | 71 | 3.1 | 70 | 3.1 | 0% (-44%, 30%) | 0.99 |
Moderate anaemia (Hb < 8 g/dL) | 14 | 0.6 | 13 | 0.6 | 6% (-100%, 60%) | 0.89 |
Fever (temp ≥ 37.5°C) | 33 | 1.4 | 28 | 1.2 | 14% (-42%, 48%) | 0.55 |
Upper respiratory tract infection | 48 | 2.1 | 49 | 2.2 | -4% (-58%, 32%) | 0.86 |
Skin/soft tissue infection | 25 | 1.1 | 21 | 0.9 | 15% (-53%, 47%) | 0.59 |
Gastroenteritis | 42 | 1.8 | 39 | 1.7 | 6% (-60%, 45%) | 0.83 |